ISPOR 2025 Poster Presentations Highlight Real-World Evidence

As healthcare decision-makers demand insights that are more representative, timely, and ready to guide action, expectations for evidence generation are quickly rising.

Even as tools and technologies continue to evolve, impactful health economics and outcomes research (HEOR) still relies on the quality, completeness, and relevance of the underlying data.

At ISPOR 2025, Inovalon researchers presented nine posters spanning oncology, chronic disease, infectious disease, and health equity. Each study was powered by robust, primary source data, including Medicare Fee-for-Service, EMRs, closed claims, and individual-level social drivers of health (SDOH), to uncover real-world opportunities to improve outcomes, reduce costs, and close care gaps.

Here’s what we shared and what it means for the future of evidence generation.

1. HCRU & costs of PARPi

Healthcare Resource Utilization (HCRU) and Costs of Poly (ADP-ribose) Polymerase Inhibitors (PARPi) as First-Line Maintenance (1LM) Treatment for Ovarian Cancer

This real-world study assessed HCRU and medical costs for 646 patients treated with 1LM PARPi monotherapy following platinum-based chemotherapy.

Findings: Patients on PARPi had fewer hospitalizations and lower medical costs in the six months after treatment began.

Impact: The findings support the value frameworks and payer engagement for maintenance therapies in oncology.

2. Microbiology testing & oral antibiotic treatment for CKD

Microbiology Testing and Oral Antibiotic Treatment Among Chronic Kidney Disease (CKD) Patients With Urinary Tract Infections: Real-World Evidence From a U.S. EMR Network

This study analyzed microbiology testing and oral antibiotic prescribing patterns in CKD patients.

Findings: Emergency settings showed lower alignment between test results and prescriptions vs. inpatient settings.

Impact: The results highlight the need to factor in test timing and improve antimicrobial stewardship.

3. HCRU costs & outcomes – SCLC

Healthcare Resource Utilization, Costs, and Outcomes Among Patients With Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) in the U.S.: A Retrospective, Real-World Analysis of Administrative Claims Data

This large-scale claims-based study evaluated patients with ES-SCLC.

Findings: Across 2,500+ patients, median survival declined by treatment line while costs remained high – driven by outpatient, pharmacy, and ER services.

Impact: The study underscores the need to re-evaluate treatment pathways and strengthen supportive care strategies in high-burden diseases.

4. Revefenacin adherence 

Differences in Demographic and Clinical Profiles Among Patients Adherent Versus Non-Adherent to Revefenacin Following a COPD-Related Hospitalization

This study examined adherence to revefenacin following COPD-related hospitalization.

Findings: Adherent patients were more likely to be older, White, and not receiving low-income subsidies. Non-adherent patients had more comorbidities like anxiety and depression.

Impact: The findings suggest key behavioral and socioeconomic factors must be addressed in care planning.

5. HCRU in patients with IPF

Real-World Healthcare Resource Utilization in Patients With Idiopathic Pulmonary Fibrosis (IPF) Initiating Antifibrotic Therapy in Medicare Fee-for-Service

This study analyzed HCRU and mortality trends in Medicare patients initiating antifibrotic therapy.

Findings: 50% of patients discontinued within 11 months and 50% died within 41 months. Hospitalizations rose post-initiation.

Impact: This study reflects the progressive nature of IPF and reinforces the importance of earlier detection and proactive care strategies.

6. SDOH in HEOR

Incorporating Social Drivers of Health Information Into Health Economics and Outcomes Research: Neighborhood-Level Proxies Versus Individual-Level Data

This study compared neighborhood-level SDOH proxies (e.g., 5-digit or 9-digit ZIP level) with person-level data.

Findings: ZIP-level data explained only a small portion of variation in person-level SDOH. Precision improves significantly with individual-level data.

Impact: The results reinforce the need for high-resolution, patient-level data to inform equitable interventions.

7. Top 5% poster: HCRU & costs study

Healthcare Resource Utilization and Costs Following Disease Progression With First-Line Systemic Therapy in Patients With Advanced Endometrial Cancer (EC) in the U.S. 

This poster, ranked in the top 5% of all submissions at the conference, examined financial and healthcare burden that follows disease progression after first-line treatment in advanced endometrial cancer.

Findings: Most patients had a treatment-free interval under six months and incurred high EC-specific costs.

Impact: The findings underscore the clinical and economic need for more effective front-line therapies.

8. Disparities in BCS

Disparities in Breast Cancer Screening Rates Are Compounded by Type of Insurance Coverage and Social Drivers of Health

Breast cancer screening is a critical component of early detection and improved survival rates. This study evaluated 7-year screening trends across insurance types and SDOH factors.

Findings: Medicaid-insured women had consistently lower screening rates, with disparities linked to income, language, geography, and education.

Impact: The study calls for structural and culturally tailored strategies to improve screening equity.

Dive deeper into the findings in our white paper.

9. MA plan design

The Importance of Medicare Advantage Plan Design and Impact on Health Equity

This study explored how different Medicare Advantage (MA) plan designs affect care access and outcomes across populations.

Findings: Healthcare plans with more thoughtful benefit structures delivered better access and affordability for underserved members.

Impact: Underscores the role of policy design in advancing equity. Early choices by new beneficiaries influence how they access and experience care.

Read our white paper for more details.

Why it matters

Across diverse conditions and care settings, our research points to three key takeaways:

• Individual-level data is essential to understanding patient journeys, access gaps, and care inequities
• Linked, longitudinal datasets unlock deeper insights for modeling, treatment evaluation, health plan design, and policy shaping
• Real-world adherence, discontinuation, and utilization patterns reveal opportunities to improve outcomes and reduce avoidable burden

As HEOR expectations evolve and payers demand clearer value demonstration, real-world evidence must be purposeful, timely, and designed to inform action.

Putting evidence into action

With curated data from 160+ primary sources and deep expertise across HEOR, real-world evidence, and analytics, we can help you:

• Generate evidence that reflects real-world care
• Uncover treatment patterns, access barriers, and unmet needs
• Demonstrate value across the product lifecycle

When the bar for evidence keeps rising, we help you clear it.

Connect with us to turn real-world data into smarter decisions.

Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.